Bifogade filer
Cinclus Pharma’s Nomination Committee proposes new representative for the company’s founders to the Board
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Cinclus Pharma Holding AB (publ) (”Cinclus Pharma”) announced today that the Nomination Committee proposes that co-founder Kjell Andersson be elected as a new member of the Board of Directors at an Extraordinary General Meeting. Kjell Andersson is proposed to succeed Peter Unge, who has expressed his wish to step down from his position on the company’s Board.
“Peter has shown great dedication to Cinclus Pharma since he, together with Kjell and others, founded the company in 2014. Now that we have reached the important milestone of initiating our first Phase III study, Peter has expressed a wish to hand over his responsibilities on the Board. We would like to express our deep appreciation for Peter’s commitment and valuable contributions to the company’s development and we are pleased that he will continue to support us as a member of Cinclus’ Scientific Advisory Board. With Kjell’s unique experience and expertise in the development of reflux treatments, we gain an extremely valuable addition to the Board while ensuring continuity within the company,” says Lennart Hansson, Chair of the Board of Cinclus Pharma.
The election of the new Board member will be addressed at an Extraordinary General Meeting intended to be held on 19 January 2026. A notice convening the meeting will be published separately ahead of the Extraordinary General Meeting. Peter Unge will remain a member of the Board until the Extraordinary General Meeting and will thereafter join Cinclus’ Scientific Advisory Board.
About Kjell Andersson
Kjell Andersson, born in 1957, is one of the founders of Cinclus Pharma. He is one of Sweden’s most experienced drug developers in acid-secretion inhibition and has played a key role in developing globally successful treatments for reflux disease. Kjell has a long background at AstraZeneca, where he served, among other roles, as preclinical project leader for the development of linaprazan, which forms the basis of Cinclus Pharma’s drug candidate linaprazan glurate. Further information about Kjell Andersson will be provided in the notice to the Extraordinary General Meeting.